Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01601470
First received: May 16, 2012
Last updated: February 8, 2013
Last verified: February 2013

May 16, 2012
February 8, 2013
September 2012
January 2013   (final data collection date for primary outcome measure)
  • Pharmacokinetics of LCZ696: Area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCtau) [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of sildenafil on the pharmacokinetics of LCZ696 (analytes of LCZ696: AHU377, LBQ657 and valsartan) will be assessed.
  • Pharmacokinetics of LCZ696: Observed maximum plasma concentration following drug administration at steady state (Cmax,ss) [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of sildenafil on the pharmacokinetics of LCZ696 (analytes of LCZ696: AHU377, LBQ657 and valsartan) will be assessed.
  • Pharmacokinetics of LCZ696: Observed minimum plasma concentration following drug administration at steady state (Cmin,ss) [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of sildenafil on the pharmacokinetics of LCZ696 (analytes of LCZ696: AHU377, LBQ657 and valsartan) will be assessed.
  • Pharmacokinetics of LCZ696: Time to reach the maximum concentration after drug administration (Tmax) [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of sildenafil on the pharmacokinetics of LCZ696 (analytes of LCZ696: AHU377, LBQ657 and valsartan) will be assessed.
  • Pharmacokinetics of Sildenafil and N-desmethyl-sildenafil: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of LCZ696 on the pharmacokinetics of Sildenafil and N-desmethyl-sildenafil will be assessed.
  • Pharmacokinetics of Sildenafil and N-desmethyl-sildenafil: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of LCZ696 on the pharmacokinetics of Sildenafil and N-desmethyl-sildenafil will be assessed.
  • Pharmacokinetics of Sildenafil and N-desmethyl-sildenafil: Terminal elimination half-life (T1/2) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of LCZ696 on the pharmacokinetics of Sildenafil and N-desmethyl-sildenafil will be assessed.
  • Pharmacokinetics of Sildenafil and N-desmethyl-sildenafil: Observed maximum plasma concentration following drug administration (Cmax) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of LCZ696 on the pharmacokinetics of Sildenafil and N-desmethyl-sildenafil will be assessed
  • Pharmacokinetics of Sildenafil and N-desmethyl-sildenafil: Time to reach the maximum concentration after drug administration (Tmax) [ Time Frame: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose from day 1 to day 7, 24 hours post-dose from day 7, day 8 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose ] [ Designated as safety issue: No ]
    The effect of co-administration of LCZ696 on the pharmacokinetics of Sildenafil and N-desmethyl-sildenafil will be assessed
Same as current
Complete list of historical versions of study NCT01601470 on ClinicalTrials.gov Archive Site
Number of patients with adverse events, serious adverse events and death [ Time Frame: From day -28 (screening) until 30 days past the final study assessment ] [ Designated as safety issue: Yes ]
Number of patients with adverse events, serious adverse events and death
Same as current
Not Provided
Not Provided
 
Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension
An Open Label, Three-period, Single Sequence Study to Evaluate the Pharmacokinetic Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension

This study is being conducted to investigate the potential for a pharmacokinetic drug-drug interaction in support of the co-administration of LCZ696 and sildenafil.

This study is being conducted to investigate the potential for a pharmacokinetic drug-drug interaction in support of the co-administration of LCZ696 and sildenafil. Furthermore, this study is being conducted to explore the potential for a pharmacodynamic interaction as measured by additive effects on cyclic Guanosine MonoPhosphate (cGMP) in urine and plasma and on blood pressure.

Interventional
Phase 2
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Mild to Moderate Hypertension
  • Drug: LCZ696
    LCZ696 400mg QD will be administerd alone for 4 days and in combination with sildenafil for 1 day
  • Drug: Sildenafil
    Sildenafil 50 mg single dose will be administerd alone for 1 days and in combination with LCZ696 400mg QD for 1 day
Experimental: Sildenafil/LCZ696/LCZ696+Sildenafil
During Treatment Period 1, on study Day 1, subjects will receive a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), subjects will receive LCZ696 once daily. In Period 3, on study Day 8, subjects will receive LCZ696 , co-administered at the same time with a single dose of sildenafil
Interventions:
  • Drug: LCZ696
  • Drug: Sildenafil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
102
January 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

-Male subjects with mild to moderate hypertension, either treated or not currently on treatment, between age 18 and 65 years of age, and otherwise in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening except for hypertension.

  • At screening: systolic blood pressure 120-140 mmHg on therapy, or 140-160 mmHg if untreated
  • At screening: diastolic blood pressure, 70-95 mmHg on therapy, or 90-100 mmHg if untreated
  • Baseline: BP ≥140/90
  • Subjects currently on hypertension treatment should be on stable single drug antihypertensive medication during 2 months prior to screening.

Exclusion Criteria:

  • Use of non-antihypertensive prescription drugs, herbal supplements, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing
  • History of documented symptomatic orthostatic hypotension or syncope

Other protocol-defined inclusion/exclusion criteria may apply.

Male
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01601470
CLCZ696B2225, 2012-001632-64
No
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP